Privately-held cell therapy company Orca Bio has announced that the US Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) seeking approval for ...

Massachusetts, USA-based Affinia Therapeutics, an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies for devastating ...

The ground shifted under China’s drugmakers when volume-based procurement cut through list prices. Margins tightened, business models wobbled, and strategy decks were rewritten overnight. The domestic ...

UK pharma major AstraZeneca has entered into a multi-target partnership with Algen Biotechnologies, the California, USA biotech announced.

US biotech AeroRx Therapeutics has secured $21 million in series A financing to advance its lead program, AERO-007, into Phase IIb testing in chronic obstructive pulmonary disease. The round was led ...

Italian biotech NanoPhoria Bioscience has announced the successful first close of its 83.5 million euros ($97.4 million) Series A financing round.

UK-based developer of novel immunoglobulin E (IgE) antibodies to treat cancer, Epsilogen, today announced the appointment of Cristina Oliva as chief medical officer (CMO). Dr Oliva is a ...

Dutch biotech uniQure recently announced that its novel gene therapy, AMT-130 (ifezuntirgene inilparvovec), demonstrated statistically-significant disease slowing in a Huntington’s disease (HD) ...

Belgian biotech Bioxodes has appointed Philippe Monteyne as chairman of its board, replacing Pierre Detrixhe. The move comes as the company advances its lead candidate BIOX-101, a recombinant peptide ...

US lobby group Pharmaceutical Research and Manufacturers of America (PhRMA) revealed that member companies, thanks to President Trump’s new tax law and regulatory streamlining, are investing $500 ...

Skye Bioscience (Nasdaq: SKYE) reported topline data from a mid-stage trial showing that its obesity drug nimacimab failed to cut weight on its own but added meaningful benefit when paired with Novo ...

AstraZeneca (LSE: AZN) has reported positive top-line results from its second Phase III trial of baxdrostat, showing the oral therapy cut blood pressure significantly in patients with ...